(Carbidopa + levodopa) is a Small Molecule owned by Amneal Pharmaceuticals, and is involved in 5 clinical trials, which were completed.
Carbidopa acts by inhibiting the activity of dopa decarboxylase and levodopa acts by enhancing the activity of dopaminergic receptors (D1A, D1B, D2, D3, D4 and D5). DOPA decarboxylase is the enzyme which converts levodopa into dopamine to stimulate the dopaminergic receptors in the brain. Carbidopa acts by inhibiting the activity of DOPA decarboxylase. This decreases the conversion of levodopa into dopamine in peripheral tissues and compensate for the depleted supply in CNS. Carbidopa also prevents the metabolism of levodopa thereby increases its bio-availability.
The revenue for (Carbidopa + levodopa) is expected to reach a total of $1.4bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the (Carbidopa + levodopa) NPV Report.
(Carbidopa + levodopa) is currently owned by Amneal Pharmaceuticals.
(Carbidopa + levodopa) Overview
IPX-203 is an extended-release formulation of carbidopa in combination with levodopa is under development for the treatment of Parkinson’s disease. The drug candidate is a small molecule. It is administered through oral route. IPX203 contains two different drugs called levodopa and carbidopa in one capsule.Levodopa acts by targeting dopaminergic receptors and carbidopa acts by targeting DOPA decarboxylase. It is developed based on controlled-release delivery technology.
Amneal Pharmaceuticals Overview
Amneal Pharmaceuticals (Amneal), formerly Amneal Pharmaceuticals, is a pharmaceutical company that develops, manufactures, markets and distribute pharmaceutical drug. It offering products includes generic and specialty pharmaceutical products. The company also offers product such as Activella, Albenza, Dexedrine, Nizatidine Oral Solution and Pyridiu in the area of oncology, inflammation and pain, central nervous system disorders, endocrinology and parasitic infections. Amneal offers products in various dosage forms such as oral solids and liquids, injectables, topicals, creams and ointments, transdermals, inhalation, ophthalmic and otic liquids and other device driven products. The company has operational presence in India, Switzerland, Ireland and the U.K. Amneal is headquartered in Bridgewater, New Jersey, the US.
The company reported revenues of (US Dollars) US$2,093.7 million for the fiscal year ended December 2021 (FY2021), an increase of 5.1% over FY2020. In FY2021, the company’s operating margin was 7.3%, compared to an operating margin of 4.6% in FY2020. In FY2021, the company recorded a net margin of 0.5%, compared to a net margin of 4.6% in FY2020. The company reported revenues of US$545.6 million for the third quarter ended September 2022, a decrease of 2.5% over the previous quarter.
Quick View – (Carbidopa + levodopa)
|Highest Development Stage|